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Ultrastable superparamagnetic core-shell nanoparticles of average diameter 80 nm have been
fabricated via a simple one-pot method involving superparamagnetic iron oxide nanoparticles
(SPIONs) core (y50 nm in diameter) and lipid bilayer shell by high energy ultrasonication. The
surface charges (zeta potentials) were measured to be between 215 mV and + 16 mV depending on
the batch composition. Anticancer drug mitomycin C (MMC) was loaded into four different samples
of variable surface charges in aqueous solution (pH = 6.8) and released in PBS buffer (pH = 7.2) at
room temperature. The kinetics of drug loading and releasing data indicated that the stable lipid
bilayer coated SPIONs (LBCSPIONs) of nearly neutral surface exhibited the highest loading (10.9 mg
of MMC/mg of materials), whereas uncoated or partially coated SPIONs of positive zeta potential
exhibited the lowest loading (2.8 and 3.5 mg MMC/mg of materials, respectively). The release
behavior of MMC was observed to be highest (5.8 mg MMC/mg of materials) from materials of
negative zeta potential compared to materials of near neutral surfaces (3.68 mg MMC/mg of
materials). The plausible mechanism of MMC loading and releasing behavior has been explained
based on the electrostatic interaction and diffusion through the lipid bilayers. To ensure
biocompatibility, the interaction of the prepared SPIONs with human cervical cancer cell line (HeLa)
was also investigated using an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
assay and ROS (reactive oxygen species) production assay and the results confirmed the super-
compatibility of LBCSPIONs.
1. Introduction
Superparamagnetic iron oxide nanoparticles (SPIONs) have
become increasingly important materials for the quick, easy,
sensitive and reliable separation of specific bio-molecules and for
magnetic hyperthermia agents in medical diagnosis and ther-
apeutics.1–4 The surface properties and the inter-particle inter-
actions are important in order to have a stable suspension of
SPIONs. One of the major problems of working on such
nanoparticles is their propensity to aggregate. Surface modifica-
tion of such nanoparticles in suspension raised an important
question: ‘‘Does the self-assembled coating of magnetic nano-
particles cover individual particles or agglomerates?’’.5 A range
of materials6–13 including liposomes14–16 have been used for
coating SPIONs for the modification of surface charge and
stability against aggregation in suspension. Sen et al.17 have
reported the stability of magnetic nanoparticles using commer-
cial dispersing agents; however, they lacked bio-compatibility for
in vivo applications such as drug delivery, magnetic hyperthermia
and magnetic contrasting due to chemical toxicity of the
dispersing agents.
Amphiphilic phospholipid molecules in water in the form of
liposomes have been well known for drug delivery for a long
time18–20 and several review papers21,22 have been published on
liposomes. Drugs can be entrapped either in the inner aqueous
phase or in the lipid bilayer, depending on their hydrophobicity
to hydrophilicity ratio. Similarly SPIONs are also well known in
the field of drug delivery23 and contrasting agents. The
advantage of using SPIONs as a drug carrier is that they can
be transported through the vascular system and can be
concentrated at a particular point of the body with the aid of
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a magnetic field.24 Recently, we have reviewed25 the importance
of SPIONs (diameter , 100 nm) for chemotherapy and drug
delivery as they can diffuse through the cell membrane. Size,
morphology and surface charge are three important parameters
for drug-loaded nanoparticles and their behaviour in the blood
stream when injected intravenously. Gupta et al.26 have reported
that nanoparticles ranging in diameter from 10 to 100 nm are
most effective for drug delivery because they can evade
reticuloendothelial system (RES) and hence their circulation
time in blood can be prolonged. Gabizon et al.27 have reported
that incorporating polyethylene glycol (PEG) to liposome bilayer
results in inhibition of liposome uptake by the reticulo-
endothelial system and significant prolongation of liposome
residence time in the blood stream. Fabrication of stable bio-
compatible SPIONs of diameter 10–100 nm with specific surface
charge and hydrophilicity is a challenge for drug delivery due to
their multifunctional properties, i.e. biocompatibility and super-
paramagnetism.
Magnetoliposomes are new class of nanocomposites for drug
delivery28–31 as they are biocompatible and magnetic. However,
most of the reports involved larger size (.100 nm) liposomes
where magnetite or maghemite nanoparticles have been
entrapped and hence could have serious diffusional limitation.
So it is always desirable to fabricate biocompatible SPIONs
under 100 nm in diameter especially for in vivo applications.26
Mitomycin C (MMC) is a molecule that has an anticancer
activity and previously been entrapped in liposomes.32 Tokunaga
et al.33 have reported the release of MMC into the blood stream
through intravenous injection. Mitomycin C is a potent
antibiotic-antineoplastic drug for ocular surgery, however it
suffers due to ocular toxicity. Chetoni et al.34 have reported that
liposomal preparation containing mitomycin C was capable of
reducing the corneal healing rate and drug toxicity of a corneal
lesion in a rabbit model. Zalipsky et al.35 have reported that
mitomycin-C-loaded STEALTH liposome (SL) has enhanced
antitumor activity compared to pure mitomycin C, pure
doxorubicin or doxorubicin-loaded SL. Recently, Cheung et al.
have reported36 the dextran-based microspheres for a loading
and release study of mitomycin C. So far no reports are available
on loading and release data on core-shell biocompatible SPIONs
of diameter less than 100 nm.
Herein is the first study that reports the fabrication of core-
shell nanoparticles of average diameter 80 nm via a simple one
step coating method involving SPIONs core and lipid bilayer
shell by high energy ultrasonication for in vitro loading and
release study of mitomycin C under physiological pH. Moreover,
the biocompatibility of the SPIONs were probed on human
cervical cancer cell line (HeLa) using MTT (3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide) assay and ROS
(reactive oxygen species) production assay.
2. Experimental
2.1 Materials
Chloroform was purchased from VWR, UK and soya phospha-
tidylcholine (SPC) was a gift by Lipoid, Switzerland. All other
chemicals were purchased from Sigma-Aldrich and used without
further purification.
2.2 Methods
Preparation of bare SPIONs and lipid bilayer coated SPIONs
(LBCSPIONs). Bare SPIONs were synthesized following
Massart method37 by co-precipitation of an aqueous solution
of ferrous and ferric chloride in the presence of ammonium
hydroxide with a slight modification which has been previously
reported17 by Sen et al.
Multilamellar liposomes (MLVs) were prepared by dissolving
270 mg of SPC phospholipid in 1 ml chloroform within a 500 mL
round bottom flask. The flask containing the phospholipid
solution was attached to a rotary evaporator (Buchi Rotavapor
R-114, Buchi, Switzerland) and immersed in a 35 uC water bath.
Upon evaporation of chloroform, a thin film of lipid formed on
the inner wall of the flask. The flask was then flushed with
nitrogen gas in order to remove chloroform residue, if any. The
film was hydrated with 27 mL of deionized water and shaken
manually for 10 min followed by annealing for 2 h at room
temperature before it can be used for the preparation of
LBCSPIONs. LBCSPIONs suspensions were prepared by
mixing SPIONs of various amounts (see Table 1) with the
MLV dispersions. The mixture was then placed under strong
ultrasonic vibration (titanium horn) for 8 min using a Vibra Cell
Sonicator (Sonics and Materials Inc., USA). The mixtures were
repeatedly cooled using ice bath during the ultrasonication.
Powder X-ray diffraction. The X-ray diffractograms of bare
SPIONs were recorded on an Inel Equinox 2000 powder
diffractometer using Cu-Ka radiation. The samples were
prepared by drying and then grinding into a fine powder. The
powder was then packed into X-ray sample holder carefully
ensuring that the surface was smooth with no visible pits or
cracks.
Magnetic measurements. Magnetic measurements were per-
formed at room temperature using an in-housed vibrating
sample magnetometer.
Transmission electron microscopy (TEM). Transmission elec-
tron micrographs (TEM) were recorded on a JEOL JEM2000EX
(JEOL, Japan) instrument operating at an accelerating voltage
200 kV and collected using Gatan software and digital camera.
Sample suspensions were placed onto a carbon-coated copper
grid using a dropping pipette and dried at RT before placing into
the TEM machine.
Fourier transform infrared spectroscopy (FT-IR). All samples
were characterized by FT-IR spectroscopy (SHIMADZU 8300,
Shimadzu Corp. Japan) with ATR attachment. A pinch of
various samples were used and the spectra were collected at RT
after 15 scans in the region of 450 to 4000 cm21.
Size and surface charge (zeta potential) analysis. Particle size
analysis was performed for all samples (bare SPIONs and
LBCSPIONs) using dynamic light scattering (Zetasizer Nano,
Malvern Instruments, UK). The same instrument was used to
analyze the zeta potential (surface charge) of the nanoparticles
using Laser Doppler Velocimetry.
















































Mitomycin C (drug) loading into the LBCSPIONs. 4 mg of
various samples (see Table S1 in ESI{) were placed in 1.5 mL
Eppendorf tubes and incubated with 1 mL of aqueous solution
of MMC having a concentration of 71 mg mL21 at 25 uC for up
to 48 h. The amount of MMC loaded into the nanomaterials at
different time intervals were determined by measuring the UV
absorption at 365 nm before and after the incubation with
nanoparticles. The concentrations of MMC were determined by
comparing the absorption (l365 nm) values with a pre-established
standard curve (see Fig. S1 in ESI) of known MMC concentra-
tions in water. MMC-loaded nanoparticles were separated from
the reaction solution by centrifugation (2000 rpm for 1 min)
followed by magnetic separation and washed with deionised
water (63, 1 mL) before being used for the release study.
Release of mitomycin C from nanomaterials in PBS buffer.
4 mg of washed nanoparticles were treated with 1 mL of PBS
buffer (pH = 7.2) at 25 uC under stirring (end-over-end rotation)
for up to 48 h. The nanoparticles were separated in different time
intervals (see Table S2 in ESI{) from the solution by centrifuga-
tion (2000 rpm for 1 min) and magnetic separation and the
absorbance was measured at 365 nm. The concentrations of
MMC in the solution were determined by comparing the
absorption (l365 nm) value with a pre-established standard curve
(see Fig. S2 in ESI) of known MMC concentrations in PBS
buffer.
In vitro biocompatibility assessment. Human cervical cancer
cells (HeLa) from the National Cell Bank of Iran (NCBI),
Pasteur Institute, were seeded on glass coverslips in 96-well
plates at 10 000 cells per well in 150 mL of medium and incubated
for 24 h. Cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine serum
(FBS) at 37 uC in a 5% CO2 incubator. It is well recognised that
the conventional in vitro examination method may contain large
errors due to the fact that nanoparticles can cause significant
changes in the cell medium, such as adsorption/denaturation of
proteins.38,39 In order to obtain reliable and reproducible results,
the modified cytotoxicity method was employed.40,41 After the
24 h incubation period, 40 mL of medium containing various
concentrations of SPIONs (i.e. 125, 250, and 500 mg ml21) was
added to the wells, and cells were incubated for additional
periods ranging from 12 h. Control cells were incubated with the
same culture medium without particles. All particle concentra-
tions and controls were each seeded in ten separate wells.
Cytotoxicity was assessed using the MTT (3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide) and ROS (reactive
oxygen species) assay.
MTT assay. After 12 h incubation of nanoparticles with the
cells, 100 mL of MTT (0.5 mg mL21) was added to each well.
















SS068 5 0 7 Unstable
SS067 0.5 7 7 Moderately stable
SS063 2.5 7 7 Stable
SS069 5 7 7 Stable
SS070 10 7 7 Moderately stable
SS073 15 7 7 Unstable
SS065 1.25 2.24 7 Stable
Fig. 1 (a) Photographs of various samples (b) size distribution of bare
SPIONs after ultrasonication (red), MLV before (green) and after (blue)
ultrasonication and LBCSPIONs SS069 (black); (c) zeta potential data of
various samples.
















































Following incubation, the medium was removed and formazan
crystals were solubilised by incubation for 20 min in 150 mL of
isopropyl alcohol. The absorbance of each well, which assesses
viable cells, was read at 545 nm on a microplate reader (Stat Fax-
2100, Awareness, Palm City, FL).
ROS production. For the determination of intracellular ROS
levels the fluorescent dye 29,79-dichlorodihydrofluorescein dia-
cetate (H2DCF-DA) (Invitrogen) was used. In the presence of
intracellular esterases this nonpolar component is converted into
the nonfluorescent polar derivative H2DCF. This intermediate is
membrane impermeable and rapidly oxidized to fluorescent 29,7-
dichlorofluorescein (DCF) by ROS. 50 mM H2DCF-DA was
added to the incubated cells–nanoparticles and the intracellular
DCF fluorescence, after 30 min, was measured with a plate
reader infinite M200 (Tecan) with an excitation wavelength of
485 nm. Emission was recorded at 535 nm. All data were
corrected for background fluorescence.
Outlier detection. The results expressed as mean (standard
deviation) of all repeats. The standard deviation values are
indicated as error bars in the MTT and ROS results plots. The
results were statistically processed for outlier detection42,43 using
a ‘‘T procedure’’ using MINITAB software (Minitab Inc., State
College, PA). One-way analysis of variance (ANOVA) with
p , 0.05 was performed for each set of test repeats. Outlier
samples have then been excluded from the corresponding assays
calculations.
3. Results and discussion
LBCSPIONs (see Table 1) were stable in suspension (see Fig. 1a)
up to the concentration of 10 mg mL21 of SPIONs during the
fabrication. Bare SPIONs (SS068) were unstable even after
strong ultrasonication. Increasing the SPIONs concentration
from 10 mg mL21 to 15 mg mL21 containing the same
concentration of MLVs during the fabrication produced
unstable suspensions (SS073).
Fig. 1b represents the particle size distribution of bare SPIONs
(SS068), MLVs before and after the ultrasonication and
LBCSPIONs (SS069). MLVs before the ultrasonication exhib-
ited a bimodal distribution with particle size ranging from 300
nm to few microns, however monomodal distribution of a size
around 30 nm was observed after high energy ultrasonication of
the MLVs. Bare SPIONs exhibited a monomodal size distribu-
tion of peak centered at around 50 nm. LBCSPIONs (SS069)
Fig. 2 TEM (left panel) of uncoated SPIONs (SS068) at top, LBCSPIONs (SS069) at the bottom; magnetic data (right panel) of bare SPIONs (SS068)
at the top and LBCSPIONs (SS069) at the bottom.
















































exhibited a monomodal size distribution of peak centered at
approximately 80 nm, indicating a clear shift in the size
distribution of SPIONs after coating with the phospholipid
bilayer. Fig. 1c presents the zeta potential data of SPIONs and
LBCSPIONs. Bare SPIONs exhibited a positive zeta potential
whereas MLVs before and after ultrasonication exhibited negative
zeta potential values. Coating SPIONs with lipid bilayer decreases
the zeta potential from positive to negative values depending on
the concentration of SPIONs in solution during the fabrication of
LBCSPIONs. Low values of zeta potential were observed on
stable LBCSPIONs with optimum concentration of SPIONs in
suspension (SS063, 069 and 070). This data indicates that the
SPIONs were coated with phospholipid up to an optimum
SPIONs concentration and the surface charge of the nanoparticles
reversed by coating with lipid.
Transmission electron micrographs (see left panel of Fig. 2)
exhibited that bare SPIONs were spherical in morphology of
sizes ranging from 30–60 nm in diameter with powder X-ray
diffraction peaks (220, 311, 400, 440) of fingerprint of pure
magnetite (Fe3O4) in the 2h range 30 to 75u (see Fig. S3 in ESI{).
The low intensity of the peaks is an indication of ultrasmall size
of magnetite. Almost closed hysteresis loops with negligible
coercivity were observed, which is indicative of the super-
paramagnetic nature of the iron oxide nanoparticles before and
after coating with lipid bilayer (see right panel of Fig. 2). The
coating of lipid bilayer had little effect on the saturation
magnetization value (y60 emu g21).
The uptake of MMC from the solution was plotted against
time and presented in Fig. 3a. It was observed that the bare
SPIONs (SS068) or LBCSPIONs (SS073) exhibited low uptake
values (,12%) of MMC from the solution. The highest uptake
(y43%) of MMC was observed for SS069 whereas SS065
exhibited an intermediate uptake value (y32%). Saturation of
MMC uptake was observed after 24 h of incubation for all
samples except for SS065 which exhibited a near saturation of
MMC uptake after around 6 h of incubation. SS069 exhibited
MMC uptake in two steps. A low uptake value (,10%) was
observed in the first seven hours of incubation whereas the
uptake value increased to saturation (42%) at 24 h of incubation.
The behavior of MMC uptake in four different materials can be
explained based on the interaction of MMC and the nanopar-
ticles surface due to their different surface charges (see later).
When MMC uptake values from four different samples were
converted to MMC loading in mg per mg of nanoparticles (see
Table S1 in ESI{), it was observed that SS069 exhibited the
Fig. 3 Kinetics of MMC load (a) and release (b) to and from bare
SPIONs and LBCSPIONs.
Fig. 4 FT-IR spectra of various samples: pure magnetite nanoparticles
SS068 (a); bi-layer coated SS069 (b); dry mitomycin C (c); and mitomycin
C loaded SS069 (d).
















































highest loading (y11 mg mg21) at saturation point after 24 h of
incubation whereas SS065 exhibited an intermediate value
(y8 mg mg21). Bare SPIONs (SS068) exhibited the lowest
MMC loading (2.8 mg mg21) and unstable LBCSPIONs (SS073)
exhibited slightly higher loading value (3.5 mg mg21).
Table S2 in ESI presents the MMC releasing data from four
different materials in PBS buffer (pH = 7.2) at 25 uC. The
amount of MMC released (mg) per mg of nanoparticles were
plotted against time (Fig. 3b). MMC release in solution quickly
reached to a saturation value within two hours for both the bare
SPIONs (SS068) and the unstable LBCSPIONs (SS073) and the
values were calculated to be 0.43 and 0.7 mg mg21, respectively.
These values were calculated to be 15.4 and 20% of the loaded
MMC in SS068 and SS073 respectively. The quick and low
percentage of MMC release from SS068 and SS073 indicate these
materials could be poor candidates for drug delivery application.
These materials were also observed to be unstable as a
suspension (see Fig. 1a) due to the aggregation of nanoparticles
and, hence, can be considered unsuitable for in vivo application
due to diffusional restriction through reticulo-endothelial
system.
SS065 exhibited the highest (y6 mg mg21) MMC release and
calculated to be 71% of the loaded MMC in SS065. This was
achieved within 10 h of incubation (Fig. 3b). SS069 exhibited a
gradual release of MMC up to 34% of the loaded drug after 48 h
of incubation. The amount of MMC released from SS069 was
calculated to be 3.7 mg mg21 after 48 h of incubation. The
highest loading of MMC in SS069 and the slow release could
make this material a potential candidate for this drug delivery
application in the in vivo context as they are stable against the
aggregation, biocompatible and superparamagnetic in nature.
Bare SPIONs exhibited a characteristic peak (Fig. 4a) at
582 cm21 due to Fe–O stretching in magnetite (Fe3O4), however
LBCSPIONs (SS069) exhibited several additional peaks (Fig. 4b)
in the region of 800 to 3500 cm21 indicating the presence of lipid
bilayer on SPIONs. Peaks at 2853 and 2922 cm21 are the
characteristics of C–H stretching of organic tail groups. Peaks at
1725 cm1 and 1052 cm21 are characteristics of CLO stretching of
aldehyde and ester groups respectively.
The effect of lipid bilayer shell in LBCSPIONs after MMC
release has also been studied by FT-IR (Fig. 4d). Fig. 4c presents
the FT-IR spectrum of pure MMC. Several peaks were observed
in the region of 1000 to 3500 cm21 with poor intensity. Peaks at
3200 to 3400 cm21 are characteristic of MMC reported by Hou
et al.44 Peaks in the region of 1500 to 1700 cm21 are
characteristic of CLO stretching and N–H bending due to the
presence of amide group. This is consistent with the structure of
mitomycin C (see Fig. 5). The FT-IR spectrum of LBCSPIONs
was nearly unchanged after MMC release study indicating that
the lipid bilayer shell or the SPIONs core was unaffected after
MMC loading and release.
Fig. 6 and 7 present the MTT assay and ROS data of HeLa
cells. The results clearly show significant differences between
various nanoparticles. According to the results, one can conclude
that the core material (i.e. sample SS068) has lower biocompat-
ibility value in comparison to the coated particles; the main
reason is the creation of free radicals by the bare surface of
SPIONs,45 which has also been confirmed by ROS results.
Moreover, it was found that the produced amount of ROS in
SS069-treated cells is lower than SS063 and SS068, resulting in
higher compatibility of SS069 compared to uncoated SS068.
Chemical structure of MMC is reported36 to contain an
aziridine ring which opens and forms a primary amine and
hydroxyl groups by hydrolysis in water (Fig. 5). Primary amine
groups later form NH3
+ ions in water and the resultant molecule
can be a positively charged species. Loading and releasing MMC
to and from LBCSPIONs can be explained based on the
interactions between the surface of the nanoparticles and the
MMC molecules. These interactions could be described as (i)
electrostatic (ionic type), (ii) physical anchoring, and (iii)
Fig. 5 Schematic representation of the structure of MMC and the
interactions between MMC and surfaces of bare SPIONs and
LBCSPIONs.
Fig. 6 MTT assay values for HeLa cells incubated with various
concentrations of different SPIONs. 1: SS068, 2:SS063, 3:SS069.
















































diffusion through the lipid membrane. Electrostatic interactions
could be either attractive (oppositely charged) or repulsive
(similarly charged). MMC is positively charged; hence it can be
easily bound to the negatively charged surface, resulting in a high
loading of MMC. Similarly, positively charged surfaces can be
poor for MMC loading due to the repulsive interaction.
Electrostatic interactions could dominate the MMC loading
behavior; however, diffusion could be a principal pathway for
neutral or low surface charge. Diffusion of MMC through the
lipid membrane could be a slow process hence loading and
release of MMC to and from the surface could have different
profile compared to electrostatic interaction. Surface of bare
SPIONs (SS068) and LBCSPIONs (SS073) were measured to be
positively charged hence a low MMC loading was observed (see
Tables S1 and S2 in ESI{) due to the repulsive interaction. A low
loading value with quick saturation time could be explained
based on the physical adsorption of MMC by anchoring to the
surface of SS068. Release behavior of MMC from the surface
was observed to be quick indicating no diffusion of MMC
through the surface. Quick saturation times during the MMC
loading (Fig. 3a) and release (Fig. 3b) to and from LBCSPIONs
(SS065) with high percentage of MMC release indicate the
interaction of MMC and surface of SS065 could be an
electrostatic attractive type (ionic bonding). In water, positively
charged MMC can be easily bound to the negatively charged
surface of SS065, and can easily be released in the presence of
negatively charged phosphate ions in PBS solution.
The surface of LBCSPIONs (SS069) was observed to have a
weak negative charge (Fig. 2b), resulting a different pattern of
MMC loading and release to and from SS069. A high value of
MMC loading with a slower rate (Fig. 3a) indicates that the
loading of MMC could be dominated by diffusion of MMC
through the membrane due to the strong affinity of drug
molecules towards the core magnetite (iron oxide surfaces).
Similarly, a low (34%) and slow MMC release profile confirms
that the MMC molecules could be entrapped.
4. Conclusions
A series of lipid bilayer coated superparamagnetic nanoparticles
(LBCSPIONs) were fabricated by a simple method using high
energy ultrasonication for eventual applications in in vivo drug
delivery. Loading and releasing of drug (mitomycin C) to and
from the LBCSPIONs were related to the surface charges and
did not have any effect on the lipid bilayer structure evidenced
from FT-IR data. The super-compatibility of LBCSPIONs
samples together with their suitable diameters (,100 nm) and
slow drug release could introduce them as promising new
magnetic materials for in vivo drug delivery.
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